Regeneron Dupixent EU Approval Expands Pediatric CSU Care
TARRYTOWN, N.Y. and PARIS, April 13, 2026 Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission has approved...
dupilumab
Advertisement
Japan Approves Dupixent for Children With Severe Asthma
TOKYO, Japan — December 23, 2025 — The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval...
Valneva Reports Strong Phase 2 Data for VLA15 Vaccine
SAINT-HERBLAIN, FRANCE — November 26, 2025. Valneva has announced positive final Phase 2 results for its Lyme disease vaccine...
EU Approves Dupixent as First Targeted CSU Therapy
TARRYTOWN, N.Y. & PARIS — November 25, 2025. The European Commission has granted landmark approval for Dupixent® (dupilumab) as...
Advertisement
